Guatemala: These 5 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Guatemala Patent 200,400,239
Patent Title: PROCEDIMIENTO PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA SOLIDA ADMINISTRABLE ORALMENTE

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Guatemala Patent 200,500,293
Patent Title: DERIVADOS DE PROSTAGLANDINAS

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 07, 2024
Generic Entry Controlled by: Guatemala Patent 200,500,078
Patent Title: POLIMORFO CRISTALINO DE ACETATO DE BAZEDOXIFENO

DUAVEE is a drug marketed by Wyeth Pharms. There are two patents protecting this drug.

This drug has twenty-two patent family members in twenty countries.

See drug price trends for DUAVEE.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Guatemala Patent 200,500,093
Patent Title: PREPARADO POLIFASICO A BASE DE UN ESTROGENO NATURAL PARA LA CONTRACEPCION

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Guatemala Patent 200,500,103
Patent Title: 4-FENILAMINO-QUINAZOLIN-6-IL-AMIDAS

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.